Treating Psoriasis with Etanercept in Italian Clinical PracticePrescribing Practices and Duration of Remission following Discontinuation

被引：0
作者：
Annalisa Arcese
Nicola Aste
Alberta Bettacchi
Germana Camplone
Franca Cantoresi
Marzia Caproni
Domenico D’Amico
Paolo Fabbri
Giorgio Filosa
Antonia Galluccio
Katharina Hansel
Paolo Lisi
Giuseppe Micali
Maria Letizia Musumeci
Massimiliano Nicolini
Aurora Parodi
Mario Patania
Michele Pezza
Concetta Potenza
Antonio Richetta
Marco Simonacci
Piergiusto Trevisan
Giancarlo Valenti
Stefano Calvieri
机构：
[1] ‘Sapienza’ University of Rome AO Sant’Andrea,Dermatological Unit
[2] University of Cagliari,Dermatological Clinic
[3] Macerata Hospital,Dermatological Unit
[4] ‘Sapienza’ University of Rome,Dermatological Clinic
[5] University of Florence,Dermatological Clinic
[6] U.O. Dermatology of Catanzaro,Dermatological Unit
[7] Jesi Hospital,Dermatological Unit
[8] Sacro Cuore di Gesu’ Fatebenefratelli Hospital,Dermatological Clinic
[9] University of Perugia,Dermatological Clinic
[10] University of Catania,Dermatological Clinic
[11] University of Genoa,Dermatological Clinic
[12] University of Trieste,Dermatological Unit, Polo Pontino
[13] ‘Sapienza’ University of Rome,Dipartimento di Malattie cutanee e veneree e Chirurgia Plastica
[14] La Sapienza Università di Roma,undefined
来源：
Clinical Drug Investigation | 2010年 / 30卷
关键词：
Psoriasis; Etanercept; Body Surface Area; Plaque Psoriasis; Dermatology Life Quality Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Conventional antipsoriatic therapies are often administered until remission, with treatment resumed in the case of relapse, in order to reduce the likelihood of cumulative, dose-dependent toxicities. Biological agents have been safely used in continuous therapy.
引用
收藏
页码：507 / 516
页数：9
相关论文
共 42 条
  • [1] Meier M.(2009)Clinical spectrum and severity of psoriasis Curr Probl Dermatol 38 1-20
  • [2] Sheth P.B.(2008)Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 826-50
  • [3] Menter A.(2007)Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris J Dtsch Dermatol Ges 5 1-119
  • [4] Gottlieb A.(2007)Skin diseases with high public health impact: psoriasis Eur J Dermatol 17 563-4
  • [5] Feldman S.R.(2006)Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus J Eur Acad Dermatol Venereol 20 988-98
  • [6] Nast A.(2003)Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2014-22
  • [7] Kopp I.B.(2003)A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 1627-32
  • [8] Augustin M.(2005)A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 1304-12
  • [9] Barker J.(2004)The efficacy and safety of etanercept in the retreatment of psoriasis after relapse [abstract P568] J Acad Dermatol 50 146-36
  • [10] Boehncke W.H.(2005)Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis Am J Clin Dermatol 6 121-233
12345